İçeriğe geç
akaturk Akademik ölçüm
Giriş Kayıt

Akademisyen

İSMAİL ENGİN

DOKTOR ÖĞRETİM ÜYESİ

İSTANBUL BEYKENT ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Endokrinoloji ve Metabolizma Hastalıkları (İç Hastalıkları)

Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.

  • Makale 14
  • Proje 0
  • Kitap 0
  • Bildiri 5
  • Patent 0
  • Sanatsal 0
Scopus (SJR) Q1 2 Q2 19 Q3 0 Q4 0
WoS (JCR) Q1 9 Q2 0 Q3 10 Q4 2
TR Index 0 makale

Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.

Üst %1 makale 2
Üst %10 makale 3
Ort. yüzdelik 59.6%
Üst %1 payı 9.1%
Üst %10 payı 13.6%

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

Dizin filtreleri

Toplam 14 yayın

Scopus (SJR)
Q1 2 Q2 19 Q3 0 Q4 0
WoS (JCR)
Q1 9 Q2 0 Q3 10 Q4 2
TR Index
0 makale

Makale listesi

  1. 2026 A comparative analysis of osteoporosis, nephrolithiasis, and metabolic/cardiovascular comorbidities in normocalcemic and mild primary hyperparathyroidism Journal of Bone and Mineral Metabolism DOI 10.1007/s00774-026-01732-0 YÖKSİS SJR Q2 JCR Q3 OpenAlex 44.9%
  2. 2026 Longitudinal Analysis of Biochemical, Imaging, and Adenoma Size Changes in Primary Hyperparathyroidism Experimental and Clinical Endocrinology & Diabetes DOI 10.1055/a-2804-1682 YÖKSİS SJR Q2 JCR Q4 OpenAlex 17.1%
  3. 2026 The Fate of Normocalcemic Hyperparathyroidism: Insights from a 3-Year Multicenter Follow-Up Hormone and Metabolic Research DOI 10.1055/a-2812-1864 YÖKSİS SJR Q2 JCR Q3 OpenAlex üst %10 OpenAlex 92.5%
  4. 2026 Turkish cross-sectional survEy of glycemic and other Metabolic parameters in patients with type 2 Diabetes in 2023: Comparison with 2018 nationwide data (TEMD-2 study). journal of diabetes and its complications DOI 10.1016/j.jdiacomp.2026.109348 YÖKSİS SJR Q2 JCR Q3 OpenAlex 46.3%
  5. 2025 Temporal Variation of Biochemical Markers and Adenoma Predictors in Normocalcemic Primary Hyperparathyroidism: A Multicenter Retrospective Analysis Clinical endocrinology (Oxford) DOI 10.1111/cen.70024. YÖKSİS SJR Q2 JCR Q3 OpenAlex 80.2%
  6. 2025 Clinical characteristics, mid-term outcomes and management of asymptomatic primary hyperparathyroidism: A multicentre retrospective cohort study Endocrine DOI 10.1007/s12020-025-04380-y YÖKSİS SJR Q2 JCR Q3 OpenAlex 16.6%
  7. 2025 Multicenter Study on the Clinical Characteristics, Diagnosis, and Treatment Outcomes of Insulinoma: Insights From 15 Medical Centres. Clinical endocrinology DOI 10.1111/cen.15255 YÖKSİS SJR Q2 JCR Q3 OpenAlex 85.9%
  8. 2025 The Triglyceride/HDL Ratio as a Non-Invasive Marker for Early-Stage NAFLD: A Retrospective Cross-Sectional Study of 2588 Patients Diagnostics DOI 10.3390/diagnostics15162045 YÖKSİS SJR Q2 JCR Q1 OpenAlex 82.5%
  9. 2025 The Impact of Metformin on BNP Levels: A Potential Cardioprotective Role in Type 2 Diabetes Journal of Clinical Medicine DOI 10.3390/jcm14082733 YÖKSİS SJR Q2 JCR Q1 OpenAlex 67.6%
  10. 2023 A rare disorder of sex development; de la chapelle syndrome DAHUDER Medical Journal DOI 10.56016/dahudermj.1216031 YÖKSİS OpenAlex 39.5%
  11. 2026 Longitudinal Analysis of Biochemical, Imaging, and Adenoma Size Changes in Primary Hyperparathyroidism Exp Clin Endocrinol Diabetes DOI https://pubmed.ncbi.nlm.nih.gov/41786304/ YÖKSİS SJR Q2 JCR Q4
  12. 2025 Clinical characteristics, mid-term outcomes and management of asymptomatic primary hyperparathyroidism: A multicentre retrospective cohort study Endocrine DOI 10.1007/s12020-025-04380-y YÖKSİS SJR Q2 JCR Q3 OpenAlex 16.6%
  13. 2025 The Triglyceride/HDL Ratio as a Non-Invasive Marker for Early-Stage NAFLD: A Retrospective Cross-Sectional Study of 2588 Patients Diagnostics DOI 10.3390/diagnostics15162045 YÖKSİS SJR Q2 JCR Q1 OpenAlex 82.3%
  14. 2025 The Triglyceride/HDL Ratio as a Non-Invasive Marker for Early-Stage NAFLD: A Retrospective Cross-Sectional Study of 2588 Patients Diagnostics DOI 10.3390/diagnostics15162045 YÖKSİS SJR Q2 JCR Q1 OpenAlex 82.3%
  15. 2025 The Triglyceride/HDL Ratio as a Non-Invasive Marker for Early-Stage NAFLD: A Retrospective Cross-Sectional Study of 2588 Patients Diagnostics DOI 10.3390/diagnostics15162045 YÖKSİS SJR Q2 JCR Q1 OpenAlex 82.3%
  16. 2025 Temporal Variation of Biochemical Markers and Adenoma Predictors in Normocalcemic Primary Hyperparathyroidism: A Multicenter Retrospective Analysis Clinical Endocrinology DOI 10.1111/cen.70024 YÖKSİS SJR Q2 JCR Q3 OpenAlex 80.2%
  17. 2025 Clinical characteristics, mid-term outcomes and management of asymptomatic primary hyperparathyroidism: A multicentre retrospective cohort study Endocrine DOI 10.1007/s12020-025-04380-y YÖKSİS SJR Q2 JCR Q3 OpenAlex 16.6%
  18. 2025 Clinical characteristics, mid-term outcomes and management of asymptomatic primary hyperparathyroidism: A multicentre retrospective cohort study Endocrine DOI 10.1007/s12020-025-04380-y YÖKSİS SJR Q2 JCR Q3 OpenAlex 16.6%
  19. 2025 The Triglyceride/HDL Ratio as a Non-Invasive Marker for Early-Stage NAFLD: A Retrospective Cross-Sectional Study of 2588 Patients DIAGNOSTICS DOI 10.3390/diagnostics15162045 YÖKSİS SJR Q2 JCR Q1 OpenAlex 82.3%
  20. 2025 The Impact of Metformin on BNP Levels: A Potential Cardioprotective Role in Type 2 Diabetes Journal of Clinical Medicine DOI 10.3390/jcm14082733 YÖKSİS SJR Q2 JCR Q1 OpenAlex 67.5%

Akademisyenlere dön